The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson’s disease: A systematic review and meta-analysis

Simran Dahiya a,b,*, Stephen Tisch a,b, Jerry Greenfield a,b

a St Vincent’s Clinical School, UNSW, Sydney, NSW, Australia
b Level 5 DeLacy Building, St Vincent’s Hospital, Victoria St, Darlinghurst, NSW, Australia

ABSTRACT

Background: Parkinson’s Disease (PD) is a progressive neurodegenerative condition associated with significant morbidity. Currently, there are limited pharmacological options and none of the therapies available are disease-modifying. This systematic review and meta-analysis considers a novel drug class through the research question – in pre-clinical rodent models of PD, is GLP-1 receptor agonist therapy neuroprotective when compared to vehicle controls?

Methods: A literature search was conducted to locate relevant pre-clinical studies. Two separate outcomes were considered. The primary outcome was indicators of dopaminergic neurotransmission. The secondary outcome was indicators of motor symptoms. Untreated PD models were compared to PD-models treated with GLP-1 receptor agonists. The final meta-analysis was conducted using the Cochrane RevMan software and represented continuous data using the inverse variance statistical method and random effects analysis model. The final study statistic was represented as an SMD value with a p-value < 0.05 considered statistically significant. Study heterogeneity and publication bias was assessed using I² values and funnel plots respectively.

Results: Eleven studies fit the inclusion criteria and were included in the final analysis. For the primary outcome (n = 128), there was a statistically significant relative improvement of dopaminergic neurotransmission (SMD 1.71, 95% CI = 0.74–2.68, p = 0.0005, I² = 76%). For the secondary outcome (n = 280), there was a statistically significant improvement in motor outcomes (SMD 2.11, 95% CI = 1.14–3.09, p < 0.0001, I² = 89%).

Conclusions: GLP-1 receptor agonist therapy is neuroprotective in pre-clinical models of PD. This study provides the clinical foundation and research support for the design of rigorous clinical trials to further investigate these results in human PD populations.

ARTICLE INFO

Keywords:
Parkinson’s Disease
GLP-1 receptor agonist
Type 2 Diabetes Mellitus

1. Introduction

Parkinson’s Disease (PD) is a progressive neurodegenerative condition characterised by the cardinal motor symptoms of bradykinesia, rigidity, tremor and postural stability [1]. PD is pathologically characterised by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain resulting in depletion of striatal dopamine and a disruption of the direct and indirect nigrostriatal motor pathways [2]. Vitally, the condition is associated with significant morbidity, motor disability and loss of independence.

Currently, there are no proven effective disease-modifying treatments and even the most potent options are purely symptomatic. None of the available therapeutic strategies impact the extent of dopaminergic cell loss or the underlying pathological processes of PD. Consequently, they are not disease-modifying, do not alter the prognostic course of the disease and are less effective against the non-motor features of PD [3]. In response to the therapeutic challenges of PD, alternative novel treatments are highly sought after and investigated. Accordingly, this systematic review and meta-analysis will consider the pre-clinical data available for the neuroprotective efficacy of the glucagon-like peptide-1 (GLP-1) receptor agonist drug class.

Within the Australian context, GLP-1 receptor agonists are currently approved by the Therapeutic Goods Administration (TGA) for the use of type 2 diabetes mellitus (T2DM). GLP-1 receptor agonists are well tolerated, and the side effects are predominantly gastrointestinal and injection-site reactions [4]. However, the mechanism of action of GLP-1 is unknown and the neuroprotective effects of GLP-1 is still being established. The hypothesis for the efficacy of GLP-1 receptor agonists as...
neuroprotective agents is founded on the evidence of the shared pathophysiology in PD and T2DM and the expression of GLP-1 receptors in brain tissue [5,6,7]. In line with the hypothesis regarding the potential neuroprotective effects of GLP-1 receptor agonists, many pre-clinical animal studies have been conducted over the last decade. Systematic reviews have inconclusively summarised the main findings of these studies and, to this date, no meta-analyses have been conducted to quantify the overall effect size from these various independent studies. It is important to note that whilst meta-analyses are uncommonly performed on pre-clinical data, they are invaluable in providing succinct information that can guide decision making in the study design of human trials.

Accordingly, this systematic review and meta-analysis will address the research question – in pre-clinical rodent models of Parkinson’s Disease, is GLP-1 receptor agonist therapy neuroprotective when compared to vehicle controls? Two outcomes will be considered. The primary outcome will focus on pathological evidence of preservation or improvement of dopaminergic neurotransmission. The second outcome will evaluate study motor outcomes. The results of each outcome will be pooled separately to determine overall effect sizes for the pre-clinical research that is currently available. Implications for future practice will be discussed in accordance.

2. Methodology

2.1. Literature search strategy

This meta-analysis considers the research question – in pre-clinical rodent models of Parkinson’s Disease, is GLP-1 receptor agonist therapy neuroprotective when compared to vehicle controls? Relevant studies were identified through database searches in Ovid Medline, PubMed, Clinicaltrials.gov, World Health Organisation International Clinical Trials Registry, Cochrane Library and Embase. Relevant search terms included: Parkinson’s Disease, GLP-1 agonist, exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide and semaglutide. An example of the search strategy is presented in Fig. 1. The search was limited to articles available in English but was not limited by date of publication. Further manual searching involved screening individual articles for relevant references and the 500 most relevant items in Google Scholar. Study abstracts were reviewed for the relevance to the use of GLP-1 receptor agonists in PD. Duplicates were removed. Full text articles were then thoroughly assessed for eligibility based on the following selection criteria.

2.2. Selection criteria

Only pre-clinical original research articles were considered. The final inclusion criteria were: 1) GLP-1 administration must be a primary intervention, 2) the GLP-1 receptor agonist specified must be Therapeutic Goods Administration (TGA) approved for T2DM, 3) the PD model must be a toxin-only model that involved administration of either 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone or 6-hydroxydopamine (6-OHDA), 4) PD toxin administration must occur prior to or simultaneous to drug therapy, 5) the PD model must be a full-lesion model, and 6) the rodent population must be normal-weight and non-diabetic.

2.3. Data extraction and critical appraisal

Two separate outcomes were considered. The primary outcome was indicators of dopaminergic neurotransmission. This included measures of striatal dopamine, tyrosine hydroxylase (TH) positive neurons in the substantia nigra pars compacta (SNpc) and the TH+ optical density in the SNpc. The secondary outcome was indicators of motor behavioural assessments. This included open-field tests, rotorod tests, catalepsy tests and apomorphine-induced rotations. For both outcomes, data was extracted from the article text, tables and figures. The data was recorded as the mean ± standard error of the mean (SEM) prior to statistical analysis. For papers where the data was not numerically presented and the authors did not return correspondence, the mean and SEM were extracted from figures using the Web Plot Digitizer software [8].

Studies were critically appraised for bias using the SYRCLE’s Risk of Bias (RoB) tool (Fig. 6), developed for animal studies as an adapted version of the Cochrane RoB tool [9]. The tool is qualitative and includes evaluation of selection bias, performance bias, detection bias, attrition bias and reporting bias. For the purposes of this meta-analysis, bias in each domain was qualitatively assessed as ‘high,’ ‘low,’ or ‘unclear.’ Studies with more than two ‘high’ bias characteristics were excluded.

2.4. Statistical analysis

The meta-analysis was conducted using the Cochrane Review Manager (RevMan) Computer Program, Version 5.4 [10]. Continuous data was represented using the inverse variance statistical method and random effects analysis model to account for differences in study design. The effect measure chosen was standard mean difference (SMD) with 95% confidence intervals (CI). Mean and SD values were entered in
RevMan for forest plot generation. For studies that compared multiple GLP-1 intervention groups to the PD control group for the same outcome, an overall intervention group mean and SD was calculated using the RevMan calculator function. For studies with the same intervention groups measuring multiple outcomes, the single most appropriate outcome from each study was chosen. This outcome was chosen from each study was chosen. This outcome was chosen. This is a table

Table 1

| Study           | Rodent | PD model                  | GLP-1 receptor agonist intervention                  | Outcome (unit of measurement)                                      | Included/not included in meta-analysis with rationale |
|-----------------|--------|---------------------------|-----------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------|
| Zhang et al. 2019 | Mouse  | MPTP (20 mg/kg/day i.p. for 30 days) | Simultaneous to PD-model induction:Semaglutide (25 nmol/kg every two days i.p. for 30 days); Liraglutide (25 nmol/kg/day i.p. for 30 days) | TH + neurons in the SNpc (cell count) | Yes – primary outcome within the study                 |
| Badawi et al. 2019 | Rat    | Rotenone (3 mg/kg/day, s.c. for 10 days) | Following PD-model induction:Liraglutide (50 μg/kg/day s.c. for 16 days) | Striatal dopamine content (pg/mg of protein) | Yes – primary outcome within the study                 |
| Zhang et al. 2018 | Mouse  | MPTP (20 mg/kg/day i.p. for 7 days) | Following PD-model induction:Semaglutide (25 nmol/kg/day every two days i.p. for 30 days);Liraglutide (25 nmol/kg/day i.p. for 30 days) | TH + neurons in the SNpc (% of non-PD vehicle control) | Yes – PD symptoms primarily caused by degeneration of dopaminergic neurons in the SNpc |
| Aksoy et al. 2017 | Rat    | Rotenone (stereotaxical infusion of 3 ug/ul in the left SNpc and the ventral tegmental area) | Following PD-model induction:Exenatide (30 μg/kg/day i.p. for 28 days) | TH + striatal optical density (% of non-PD vehicle control) | No – non-independent secondary study outcome |
| Badawi et al. 2017 | Rat    | Rotenone (3 mg/kg/day s.c. for 10 days) | Following PD-model induction:Liraglutide (50 μg/kg/day s.c. for 16 days) | Striatal dopamine content (ng/mg of protein) | No – non-independent secondary study outcome |
| Hansen et al. 2016 | Rat    | 6-OHDA (stereotaxical infusion of 13.5 ug in the right medial forebrain bundle) | Following PD-model induction:Liraglutide (500 μg/kg/day s.c. for 6 weeks) | TH + neuron in the SNpc (cell count) | Yes – primary outcome within the study                 |
| Harkavy et al. 2008 | Rat    | 6-OHDA (stereotaxical infusion of 8ug/4ul in the right medial forebrain bundle) | Following PD-model induction:Exendin-4 (0.5 ug/kg twice daily i.p. for 7 days) | Striatal dopamine content (pg/g of protein) | Yes – primary outcome within the study                 |
| Zhang et al. 2020 | Rat    | Rotenone (stereotaxical infusion of 8ug in the right medial forebrain bundle) | Following PD-model induction:Exendin-4 (10 nmol/kg/day i.p. for 30 days) | Striatal dopamine content (pg/mg of protein) | No – non-independent secondary study outcome |
| Feng et al. 2018 | Mouse  | MPTP (25 mg/kg/2h i.p. for 8 h) | Following PD-model induction:Liraglutide (25 nmol/kg/day i.p. for 6 days) | TH + density in the SNpc (optical density) | Yes – primary outcome within the study                 |
| Yuan et al. 2017 | Mouse  | MPTP (25 mg/kg/day i.p. for 7 days) | Following PD-model induction:Liraglutide (25 nmol/kg/day i.p. for 7 days) | TH + density in the striatum (optical density) | Yes – PD symptoms primarily caused by degeneration of dopaminergic neurons in the SNpc |
| Liu et al. 2015 | Mouse  | MPTP (20 mg/kg/day i.p. for 7 days) | Simultaneous to PD-model induction:Liraglutide (25 nmol/kg/day i.p. for 14 days);Lixisenatide (10 nmol/kg/day i.p. for 14 days);Exendin-4 (10 nmol/kg/day i.p. for 14 days) | TH + neurons in the SNpc (cell count) | Yes – PD symptoms primarily caused by degeneration of dopaminergic neurons in the SNpc |

Table 2

Distribution of study characteristics for the primary outcome.

| PD model | GLP-1 receptor agonist intervention | Number of studies |
|----------|------------------------------------|-------------------|
| 6-OHDA   | Liraglutide                        | 8                 |
| MPTP     | Exenatide/exendin-4                | 3                 |
| Rotenone | Semaglutide                        | 2                 |
|          | Lixisenatide                       | 1                 |

| Outcome                                      | Number of studies |
|----------------------------------------------|-------------------|
| TH + neurons in the SNpc (cell count)        | 6                 |
| Striatal dopamine content (pg/mg of protein) | 2                 |
| TH + density in the SNpc (optical density)   | 2                 |
3. Results

3.1. Search results

The search strategy resulted in 387 articles. 40 relevant records were screened for their relevance to GLP-1 receptor agonist use in PD. The final number of studies included in the analysis was 11 (Fig. 2) [11–21]. Articles were mainly excluded due to study design variations. Partial PD lesion models and study designs in which drug therapy was given prior to establishing a PD lesion were eliminated as the study is specific for the effect of GLP-1 receptor agonists on established PD lesions. Diabetic rodent populations were excluded due to potential additional mechanistic factors. Experimental GLP-1 receptor agonists with an unknown human safety profile that are not TGA-listed were excluded to optimise the applicability of this review to Phase IV human clinical trials.

3.2. Characteristics of included studies

3.2.1. Dopaminergic neurotransmission outcomes

Table 1 displays the study characteristics of studies included in the primary outcome measuring indicators of dopaminergic neurotransmission. As the pathogenesis of PD is typically characterised by dopaminergic neuron degeneration in the SNpc, study outcomes were chosen accordingly. TH is the rate-limiting enzyme in the synthesis of dopamine and is hence used as the marker for dopaminergic neurons in pre-clinical studies [2]. Chosen study outcomes thus included cell count of TH+ neurons in the SNpc and optical density of TH+ density in the SNpc. In studies that lacked a measure of SNpc dopaminergic neurotransmission, striatal dopamine was considered.

Table 2 summarises the distribution of variables within the studies – PD model choice, GLP-1 receptor agonist therapy choice and dopaminergic neurotransmission outcomes. To determine the publication bias of studies, the funnel plot generated for these outcomes is displayed in Fig. 3.

![PRISMA flow chart of search strategy and study selection](image-url)
3.2.2. Motor assessment outcomes

Table 3 displays the study characteristics of studies included in the secondary outcome considering motor symptoms. The study outcomes considered include the open-field test, the rotarod test, the apomorphine-induced rotations test and the catalepsy test. The open-field test is a measure of general locomotor activity, recording ambulations over a period of time [11]. The rotarod test is a more specific measure of motor coordination, specifically bradykinesia and imbalance [11]. Similarly, the catalepsy test is also a more specific test focusing on the symptoms of akinesia and rigidity [15]. The apomorphine-induced rotations test does not represent a specific Parkinsonian symptom but is the best indicator of motor impairment in unilateral full lesion models by determining the severity of the lesion [16]. Other tests were less commonly performed and were excluded from the meta-analysis.

Table 4 summarises the distribution of variables within the studies –

| Study                        | Rodent | PD model                                   | GLP-1 receptor agonist intervention | Outcome (unit of measurement) | Included/not included in meta-analysis with rationale |
|------------------------------|--------|--------------------------------------------|-------------------------------------|-------------------------------|------------------------------------------------------|
| Zhang et al. 2019            | Mouse  | MPTP (20 mg/kg/day i.p. for 30 days)       | Simultaneous to PD-model induction: Semaglutide (25 nmol/kg every two days i.p. for 30 days); Liraglutide (25 nmol/kg/day i.p. for 30 days) | Open field test (metres/10 min) | Yes – indicator of general locomotor and exploratory activity; No – non-independent secondary study outcome |
| Badawi et al. 2019           | Rat    | Rotene (3 mg/kg/day, s.c. for 10 days)     | Following PD-model induction: Liraglutide (50 μg/kg/day s.c. for 16 days) | Open field test (ambulations/5 min) | Yes – primary outcome within the study |
| Zhang et al. 2018            | Mouse  | MPTP (20 mg/kg/day i.p. for 7 days)        | Following PD-model induction: Semaglutide (25 nmol/kg every two days i.p. for 7 days); Liraglutide (25 nmol/kg/day i.p. for 7 days) | Open field test (cm/10 min) | Yes – indicator of general locomotor and exploratory activity; No – non-independent secondary study outcome |
| Aksoy et al. 2017            | Rat    | Rotene (sterotaxical infusion of 3ug/ul in the left SNpc and the ventral tegmental area) | Following PD-model induction: Exenatide (30 ug/kg/day i.p. for 28 days) | Apomorphine-induced rotations (turns/10 min) | Yes – primary outcome within the study |
| Badawi et al. 2017           | Rat    | Rotene (3 mg/kg/day s.c. for 10 days)      | Following PD-model induction: Liraglutide (50 μg/kg/day s.c. for 16 days) | Cylindrical test (rears/5 min) | No – non-independent secondary study outcome |
| Hansen et al. 2016           | Rat    | 6-OHDA (stereotaxical infusion of 13.5 ug in the medial forebrain bundle) | Following PD-model induction: Liraglutide (500 ug/kg/day s.c for 6 weeks) | Apomorphine-induced rotations (turns/15 min) | Yes – primary outcome within the study |
| Harkavyi et al. 2008         | Rat    | 6-OHDA (stereotaxical infusion of 8ug/ul in the right medial forebrain bundle) | Following PD-model induction: Exendin-4 (3 μg/kg twice daily i.p. for 7 days) | Apomorphine-induced rotations (turns/15 min) | Yes – primary outcome within the study |
| Zhang et al. 2020            | Rat    | 6-OHDA (stereotaxical infusion of 3ul in the right medial forebrain bundle) | Following PD-model induction: Exendin-4 (10 nmol/kg/day i.p. for 30 days) | Open field test (cm/10 min) | No – non-independent secondary study outcome |
| Feng et al. 2018             | Mouse  | MPTP (25 mg/kg/2h i.p. for 8 h)            | Following PD-model induction: Liraglutide (25 nmol/kg/day i.p. for 6 days) | Apomorphine-induced rotations (turns/30 min) | Yes – the apomorphine-induced rotations test is a better indicator of PD severity in unilateral lesion models |
| Yuan et al. 2017             | Mouse  | MPTP (25 mg/kg/day i.p. for 7 days)        | Following PD-model induction: Liraglutide (25 nmol/kg/day i.p. for 7 days) | Rotarod test (s) | Yes – primary outcome within the study |
| Liu et al. 2015              | Mouse  | MPTP (20 mg/kg/day i.p. for 7 days)        | Simultaneous to PD-model induction: Liraglutide (25 nmol/kg/day i.p. for 14 days); Lixisenatide (10 nmol/kg/day i.p. for 14 days); Exendin-4 (10 nmol/kg/day i.p. for 14 days) | Rotarod test (s) | Yes – primary outcome within the study |

PD model choice, GLP-1 receptor agonist therapy choice and motor test. The funnel plot generated for these outcomes is displayed in Fig. 4. Like the primary outcome, the funnel plot for the secondary outcome is visually asymmetrical indicating the presence of publication bias or high heterogeneity.
3.3. Meta-analysis for dopaminergic neurotransmission outcomes

Based on 10 studies (n = 128), the forest plot for the primary outcome (Fig. 5a) revealed that GLP-1 receptor agonist therapy was neuroprotective in pre-clinical PD models, seen through a statistically significant relative improvement of dopaminergic neurotransmission (SMD 1.71, 95% CI = 0.74–2.68, p = 0.0005). The study heterogeneity is high (I² 76%, p < 0.0001) and subgroup analysis was statistically insignificant.

3.4. Meta-analysis for motor assessment outcomes

Based on 11 studies (n = 280), the forest plot for the secondary outcome (Fig. 5b) revealed that GLP-1 receptor agonist therapy was also neuroprotective in pre-clinical PD models when comparing motor outcomes (SMD 2.11, 95% CI = 1.14–3.09, p < 0.0001). Study heterogeneity is higher than the primary outcome (I² 89%, p < 0.0001) and subgroup analysis was statistically insignificant.

4. Discussion

4.1. Main findings

GLP-1 receptor agonist therapy is neuroprotective in pre-clinical rodent models of PD. As demonstrated in the forest plots, the overall effect size is positive for both motor outcomes and indicators of dopaminergic neurotransmission despite variations in study outcomes and study design. GLP-1 receptor agonist therapy was shown to increase both the presence of dopaminergic neurons and striatal dopamine indicating an improvement in the neurotransmission of the entire nigrostriatal pathway. The clinical impact of these pathological findings was considered through the secondary outcome assessing change in motor outcomes. There was a general trend of improvement reported for each separate motor outcome in most studies. Combining these parameters indicated an overall improvement in motor activity that encapsulates the varying motor symptoms of PD.

In some studies, the impact of GLP-1 receptor agonist therapy given following PD model induction showed a restoration of dopaminergic neurons comparable to the non-Parkinsonian vehicle controls. For instance, the 2018 study conducted by Zhang et al. evaluated the effect of liraglutide and semaglutide on the MPTP mouse model. On histological assessment, TH+ neuron count was recorded and expressed as a percentage of the non-Parkinsonian vehicle control. Whilst the PD model without intervention had a mean dopaminergic neuronal percentage of 59.18% (SEM 9.391, p < 0.001 compared to non-PD control), this value increased to 75.61% (SEM 13.319, p < 0.01 compared to MPTP group) and 88.56% (SEM 7.869, p < 0.001 compared to MPTP group) with liraglutide and semaglutide treatment respectively [13]. In studies such as this one, GLP-1 receptor agonist therapy was initiated following the establishment of a PD lesion indicating that GLP-1 receptor agonist therapy may be disease-modifying and could alter the prognostic course and slow the progression of PD.

4.2. Study limitations

This review has limitations related to the statistical analysis of animal studies. First, the pooled forest plots for both outcomes have high study heterogeneity.

Fig. 5. Forest plots comparing a) dopaminergic neurotransmission outcomes, and b) motor outcomes between PD models and PD models treated with a GLP-1 receptor agonist.
heterogeneity values that are not resolved through subgroup analyses. The purpose of this meta-analysis was to consider a broader, clinically relevant research question than those proposed by the individual studies alone. For instance, considering the motor outcomes for rotarod test performance only, whilst resolving study heterogeneity values, is not as relevant for a clinician interested in overall motor improvement. Further, whilst many clinical symptoms in human trials are often standardised against rating scales and set protocols, animal studies are more flexible and less consistent in their study design. As a consequence, animal studies are likely to be inherently more heterogeneous when considering variances in animal models, intervention protocols and chosen study outcomes [22]. In this review, three different PD model toxins were considered over two rodent species with variations in the study design for PD model induction and GLP-1 receptor agonist therapy. Further, distinct but related study outcomes were integrated into a more general assessment of behavioural and histological improvements.

As a consequence, the high heterogeneity for these studies is explained by slight variations in study design but is considered appropriate given the clinical relevance of the broader questions asked. The high heterogeneity values also likely accounts for the asymmetry of the funnel plots [23]. However, publication bias in animal studies and studies performed with small sample sizes is common. Publication bias, consequently, must be considered as an influencing factor in the interpretation of the results of this meta-analysis.

Whilst being a necessary step in the general scheme of research, another limitation of animal studies is their shortcomings in modelling human pathology. Ideally, the model should reflect the main pathophysiological changes in PD. However, none of the included PD models in this meta-analysis completely replicate these pathologies [24,25]. Further, animal models are also expected to mimic the symptomology of PD. Some motor symptoms were not directly translatable or assessable, such as tremor and postural stability. Non-motor symptoms were

---

**Fig. 6.** SYRCLE’s Risk of Bias tool [9].

| Item | Type of bias | Domain | Description of domain | Review authors judgment |
|------|--------------|--------|-----------------------|-------------------------|
| 1    | Selection bias | Sequence generation | Describe the methods used, if any, to generate the allocation sequence in sufficient detail to allow an assessment whether it should produce comparable groups. | Was the allocation sequence adequately generated and applied? (*) |
| 2    | Selection bias | Baseline characteristics | Describe all the possible prognostic factors or animal characteristics, if any, that are compared in order to judge whether or not intervention and control groups were similar at the start of the experiment. | Were the groups similar at baseline or were they adjusted for confounders in the analysis? |
| 3    | Selection bias | Allocation concealment | Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen before or during enrolment. | Was the allocation adequately concealed? (*) |
| 4    | Performance bias | Random housing | Describe all measures used, if any, to house the animals randomly within the animal room. | Were the animals randomly housed during the experiment? |
| 5    | Performance bias | Blinding | Describe all measures used, if any, to blind trial caregivers and researchers from knowing which intervention each animal received. Provide any information relating to whether the intended blinding was effective. | Were the caregivers and/or investigators blinded from knowledge which intervention each animal received during the experiment? |
| 6    | Detection bias | Random process | Describe whether or not animals were selected at random for outcome assessment, and which methods to select the animals, if any, were used. | Were animals selected at random for outcome assessment? |
| 7    | Detection bias | Blinding | Describe all measures used, if any, to blind outcome assessors from knowing which intervention each animal received. Provide any information relating to whether the intended blinding was effective. | Was the outcome assessor blinded? |
| 8    | Attrition bias | Incomplete outcome data | Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized animals), reasons for attrition or exclusions, and any re-inclusions in analyses for the review. | Were incomplete outcome data adequately addressed? (*) |
| 9    | Reporting bias | Selective outcome report | State how selective outcome reporting was examined and what was found. | Are reports of the study free of selective outcome reporting? (*) |
| 10   | Other | Other sources of bias | State any important concerns about bias not covered by other domains in the tool. | Was the study apparently free of other problems that could result in high risk of bias? (*) |
disregarded altogether as any animal study design would be unreliable in measuring factors such as mood and sleep disturbance. Hence, statistically significant results in animal studies may not translate to clinical significance due to limitations of the PD model. Nonetheless, animal studies are an invaluable resource that indicate the opportunity for further research and are often the first stage to constructing studies that confirm a clinically measurable effect of an intervention in human populations.

4.3. Implications for clinical practice

This meta-analysis, despite its limitations, has demonstrated that GLP-1 receptor agonist therapy is effective in reducing motor impairments and improving dopaminergic transmission in rodent models of PD. Importantly, the safety profiles of GLP-1 receptor agonists have already been identified and the drug class has been approved for human use. Consequently, there is sufficient research to justify human trials to determine the clinical outcomes of GLP-1 receptor agonist therapy in a human PD population.

Currently, the UCL Queen Square Institute of Neurology has been the only centre to address this available field of research and publish the outcomes of human clinical trials. Consistent with the results of this meta-analysis, the research team found that there was a statistically and clinically significant improvement observed for motor symptoms [26–28]. However, the evidence at this stage is insufficient to change clinical practice and further trials must be performed. If the results of future trials are successful, the approved use of GLP-1 receptor agonist therapy could be extended to include PD patients and GLP-1 receptor agonist therapy could become the first disease-modifying pharmacological option for PD.

4.4. Gaps in the literature

Currently, there are many gaps in the available literature that must be addressed before GLP-1 receptor agonist therapy is approved for use in PD patients. Primarily, there is a lack of information regarding long-term neurological outcomes. The longest pre-clinical study was run by Hansen et al. in 2016 and was conducted over 6 weeks [16]. Similarly, the longest human trial was conducted in 2013 and involved the administration of exenatide over 12 months, followed by a 12-week wash-out and follow-up outcomes measured at 24 months [26,27]. There is also a lack of information regarding the side effect profile of GLP-1 receptor agonist use in non-diabetic populations. Weight loss was a significant finding in the published human trials and was seen to occur during administration and to reverse following discontinuation [27]. However, this evidence is limited. Some potential side effects, such as hypoglycaemia, have not been studied at all. Conversely, there is only a single pre-clinical study and no human clinical studies looking at the impact of the therapy in patients that have both T2DM and PD [29]. Both conditions are common, have a shared pathophysiological basis and are likely to co-exist. Further, given that the side effect profile is known to be tolerable in these patients, this would be a valuable sector of research. Within the Australian context, many patients may already be eligible for GLP-1 receptor agonist therapy under the Pharmaceutical Benefits Scheme (PBS) guidelines and if the drug class is proven to be effective, adjustment of their diabetic medications would be a simple task. Finally, studies that are available have limited information regarding non-motor symptom outcomes and are composed of small study numbers. Thus, to establish the efficacy of GLP-1 receptor agonist therapy in PD, a large double-blinded RCT must be conducted that administers the therapy over a longer period of time with long-term follow-up data. There must be a larger range of outcomes measured with an extensive analysis of recorded side effects.

References

[1] K.L. Chou, Clinical manifestations of Parkinson disease. <https://www.uptodate.com/contents/clinical-manifestations-of-parkinson-disease?search=parkinsons%20disease&selectedTitle=1-150&usage_type=default&display_rank=1#H18> (accessed 01.09.2020).
[2] J. Jankovic, Etiology and pathogenesis of Parkinson Disease. <https://www.uptodate.com/contents/etiology-and-pathogenesis-of-parkinson-disease?search=parkinsons%20disease&selectedTitle=1-150&usage_type=default&display_rank=5> (accessed 01.09.2020).
[3] Y. Smith, T. Wichmann, S.A. Factor, M.R. DeLong, Parkinson’s disease therapeutics: new developments and challenges since the introduction of levodopa, Neuro-rhynchopharmacology 37 (2012) 213–246.
[4] H. Kelly, et al., Type 2 diabetes in adults. <https://pubmed.ncbi.nlm.nih.gov/22655771/> (accessed 01.09.2020).
[5] A. Khalilnezhan, D. Taskiran, The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exendin-4 against glucose and fructose-induced neurotoxicity, Int J Neurosci 129 (2019) 481–491.
[6] X. Yue, H. Li, H. Yan, P. Zhang, L. Chang, L. Tong, Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies, Medicine (Baltimore) 95 (2016), e5949.
[7] E. Cereda, M. Barichelli, C. Pedrolli, C. Klersy, E. Cassani, R. Caccianlanza, G. Pezzoli, Diabetes and risk of Parkinson’s disease: a systematic review and meta-analysis, Diabetes Care 34 (2011) 2614–2623.
[8] A. Rohatgi, WebPlotDigitizer. <http://automeris.io/WebPlotDigitizer/citation.html> (accessed 01.09.2020).
[9] C.R. Hooijmans, M.M. Rovers, R.B.M. de Vries, M. Leenaars, M. Ritskes-Hoitinga, M.W. Lageman, SYRCLE’s risk of bias tool for animal studies, BMC Med Res Methodol 14 (2014) 4.
[10] [Computer Program]. Review Manager (RevMan) Version 5.4. The Cochrane Collaboration, 2020.
[11] L. Zhang, Ling Yu Zhang, L. Li, C. Höchler, Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease, J Parkinsons Dis 9 (9) (2019) 157–171.
[12] G.A. Badawi, M.A. Abd El Fatah, H.F. Zaki, M.I. El Sayed, Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats, Neurons Res 35 (3) (2019) 635–653.
[13] L. Zhang, L. Zhang, L. Li, C. Höchler, Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson’s disease mouse model, Neuropeptides 71 (2018) 70–80.
[14] D. Aksey, V. Solnitz, T. Cavugoglu, A. Meral, U. Ateş, O. Erbaş, Neuroprotective Effects of Exenatide in a Rotenone-Induced Rat Model of Parkinson’s Disease, Am J Med Sci 354 (3) (2017) 319–324.
[15] G.A. Badawi, M.A. Abd El Fatah, H.F. Zaki, M.I. El Sayed, Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease, Inflammopharmacology 25 (3) (2017) 369–382.
[16] H.H. Hansen, K. Fabricius, P. Barkholt, J.D. Mikkelsen, J. Jelsing, C. Pyke, L. Knudsen, N. Vrang, Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson’s disease, Brain Res 1646 (2015) 364–365.
[17] A. Harkavy, A. Aburumelieh, R. Lever, A.E. Kingsbury, C.S. Biggs, P.S. Whittton, Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease, J Neuroinflammation 5 (2008) 15.
[18] L. Zhang, Q. Jin, L. Lin, The GLP-1/GIP dual receptor agonist DA5-CH is superior to Exendin-4 in protecting neurons in the 6-OHDA rat Parkinson Model, ResearchGate (2020).
[19] P. Feng, X. Zhang, D. Li, C. Li, Z. Yuan, R. Wang, G. Xue, G. Li, C. Höchler, Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson’s disease, Neuropharmacology 123 (2018) 385–394.
[20] Z. Yuan, D. Li, P. Feng, G. Xue, C. Ji, G. Li, C. Höchler, A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson’s disease, Eur J Pharmacol 812 (2017) 82–90.
[21] W. Liu, J. Jalewa, M. Sharma, G. Li, L. Li, C. Höchler, Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease, Neuroscience 303 (2015) 42–50.
[22] C.R. Hooijmans, J. Int Hout, M. Ritskes-Hoitinga, M.M. Rovers, Meta-analyses of animal studies: an introduction of a valuable instrument to further improve healthcare, Ilar J 55 (2014) 418–426.
[23] J.A.C. Sterne, A.J. Sutton, J.P.A. Ioannidis, N. Terrin, D.R. Jones, J. Lau, J. Carpenter, G. Rucker, R.M. Harbord, C.H. Schmid, J. Tetzlaff, J.J. Deeks, J. Peters, P. Mavrisaki, G. Schwarzer, S. Duval, D.G. Altman, D. Moher, J.P.T. Higgins, Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials, BMJ 343 (2011) d4002.
[24] J.A. Potashnik, S.R. Blame, N.K. Runkle, Limitations of animal models of Parkinson’s disease, Parkinsons Dis 2011 (2010), 569083.
[25] E.A. Konnova, M. Swanson, Animal Models of Parkinson’s Disease, in: T.B. Stoker, J.C. Greendale (Eds.), Parkinson’s Disease: Pathogenesis and Clinical Aspects, Codon Publications, 2018, pp. 83–106.
[26] I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djambidjan, P. Ell, T. Soderlund, P. Whitton, R. Wyse, I. Tasca, A. Lees, P. Limousin, T. Foltynie, Exenatide and the treatment of patients with Parkinson’s disease, J Clin Invest 123 (6) (2013) 2730–2736.
[27] I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, J. Kahan, P. Ell, P. Whitton, R. Wyse, T. Isaac, A. Lees, P. Limousin, T. Foltynie, Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease, J Parkinsons Dis 4 (3) (2014) 337–344.

[28] D. Athauda, K. Maclagan, S.S. Skene, M. Bajwa-Joseph, D. Letchford, K. Chowdhury, S. Hibbert, N. Budnik, L. Zampedri, J. Dickson, Y. Li, I. Aviles-Olmos, T. Warner, P. Limousin, A.J. Lees, N.H. Greig, S. Tebbs, T. Foltynie, Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial, The Lancet 390 (2017) 1664–1675.

[29] E.A. Elbassuoni, R.F. Ahmed, Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson’s with pre-existing diabetes, Neurochem Int 131 (2019), 104583.

[30] D. Moher, A. Liberati, J. Tetzlaff, D.G. Ahman, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement, PLOS Medicine 6 (7) (2009) e1000097.